DNA-dependent protein kinase and ataxia telangiectasia mutated (ATM) promote cell survival in response to NK314, a topoisomerase IIα inhibitor

Molecular Pharmacology

Volumn 80, Issue 2, 2011, Pages 321-327

  Guo, Lei ^a,b   Liu, Xiaojun ^a   Jiang, Yingjun ^a   Nishikawa, Kiyohiro ^c   Plunkett, William ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c NIPPON KAYAKU CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 6 (1 THIANTHRENYL) 4 PYRANONE; 4 HYDROXY 5 METHOXY 2,3 DIHYDRO 1H [1,3]BENZODIOXOLO[5,6 C]PYRROLO[1,2 F]PHENANTHRIDIUM CHLORIDE; ATM PROTEIN; BRCA2 PROTEIN; DNA; DNA DEPENDENT PROTEIN KINASE; DNA DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT KU80; GYRASE INHIBITOR; HISTONE H2AX; NK 314; UNCLASSIFIED DRUG; XRCC3 PROTEIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL ASSAY; CELL SURVIVAL; CLONOGENIC ASSAY; CONTROLLED STUDY; DNA REPAIR; DNA UNWINDING ASSAY; DOUBLE STRANDED DNA BREAK; DRUG STRUCTURE; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PULSED FIELD GEL ELECTROPHORESIS; WILD TYPE;

ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; ATAXIA TELANGIECTASIA; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL SURVIVAL; DNA TOPOISOMERASES, TYPE II; DNA-ACTIVATED PROTEIN KINASE; DNA-BINDING PROTEINS; HUMANS; PHENANTHRENES; PROTEIN-SERINE-THREONINE KINASES; TOPOISOMERASE INHIBITORS; TUMOR SUPPRESSOR PROTEINS;

EID: 79960208810     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.109.057125     Document Type: Article

References (42)

1. Ahnesorg P, Smith P, and Jackson SP (2006) XLF interacts with the XRCC4-DNA ligase IV complex to promote DNA nonhomologous end-joining. Cell 124:301-313. (Pubitemid 43121979)
2. Anderson CW, Dunn JJ, Freimuth PI, Galloway AM, and Allalunis-Turner MJ (2001) Frameshift mutation in PRKDC, the gene for DNA-PKcs, in the DNA repair-defective, human, glioma-derived cell line M059J. Radiat Res 156:2-9. (Pubitemid 32641616)
3. Azarova AM, Lyu YL, Lin CP, Tsai YC, Lau JY, Wang JC, and Liu LF (2007) Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies. Proc Natl Acad Sci USA 104:11014-11019. (Pubitemid 47175218)
4. Bauer WR (1978) Structure and reactions of closed duplex DNA. Annu Rev Biophys Bioeng 7:287-313.
5. Bishop DK, Ear U, Bhattacharyya A, Calderone C, Beckett M, Weichselbaum RR, and Shinohara A (1998) Xrcc3 is required for assembly of Rad51 complexes in vivo. J Biol Chem 273:21482-21488. (Pubitemid 28405315)
6. Bonner WM, Redon CE, Dickey JS, Nakamura AJ, Sedelnikova OA, Solier S, and Pommier Y (2008) GammaH2AX and cancer. Nat Rev Cancer 8:957-967.
7. Carter BZ, Milella M, Altieri DC, and Andreeff M (2001) Cytokine-regulated expression of survivin in myeloid leukemia. Blood 97:2784-2790.
8. Chen L, Trujillo K, Sung P, and Tomkinson AE (2000) Interactions of the DNA ligase IV-XRCC4 complex with DNA ends and the DNA-dependent protein kinase. J Biol Chem 275:26196-26205.
9. Collis SJ, DeWeese TL, Jeggo PA, and Parker AR (2005) The life and death of DNA-PK. Oncogene 24:949-961. (Pubitemid 40313872)
10. Cortez D, Wang Y, Qin J, and Elledge SJ (1999) Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks. Science 286:1162-1166.
11. Cowell IG, Durkacz BW, and Tilby MJ (2005) Sensitization of breast carcinoma cells to ionizing radiation by small molecule inhibitors of DNA-dependent protein kinase and ataxia telangiectsia mutated. Biochem Pharmacol 71:13-20. (Pubitemid 41713522)
12. Davies AA, Masson JY, McIlwraith MJ, Stasiak AZ, Stasiak A, Venkitaraman AR, and West SC (2001) Role of BRCA2 in control of the RAD51 recombination and DNA repair protein. Mol Cell 7:273-282. (Pubitemid 32206495)
13. Ding J, Miao ZH, Meng LH, and Geng MY (2006) Emerging cancer therapeutic opportunities target DNA-repair systems. Trends Pharmacol Sci 27:338-344. (Pubitemid 43870126)
14. Durocher D and Jackson SP (2001) DNA-PK, ATM and ATR as sensors of DNA damage: variations on a theme? Curr Opin Cell Biol 13:225-231.
15. Ewald B, Sampath D, and Plunkett W (2007) H2AX phosphorylation marks gemcitabine-induced stalled replication forks and their collapse upon S-phase checkpoint abrogation. Mol Cancer Ther 6:1239-1248. (Pubitemid 46711987)
16. Furuta T, Takemura H, Liao ZY, Aune GJ, Redon C, Sedelnikova OA, Pilch DR, Rogakou EP, Celeste A, Chen HT, et al. (2003) Phosphorylation of histone H2AX and activation of Mre11, Rad50, and Nbs1 in response to replication-dependent DNA double-strand breaks induced by mammalian DNA topoisomerase I cleavage complexes. J Biol Chem 278:20303-20312. (Pubitemid 36799229)
17. Guo L, Liu X, Nishikawa K, and Plunkett W (2007) Inhibition of topoisomerase IIalpha and G2 cell cycle arrest by NK314, a novel benzo[c]phenanthridine currently in clinical trials. Mol Cancer Ther 6:1501-1508. (Pubitemid 46957409)
18. Hickson I, Zhao Y, Richardson CJ, Green SJ, Martin NM, Orr AI, Reaper PM, Jackson SP, Curtin NJ, and Smith GC (2004) Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res 64:9152-9159. (Pubitemid 39665530)
19. Jazayeri A, Falck J, Lukas C, Bartek J, Smith GC, Lukas J, and Jackson SP (2006) ATM- and cell cycle-dependent regulation of ATR in response to DNA doublestrand breaks. Nat Cell Biol 8:37-45. (Pubitemid 43064795)
20. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, and Craig RW (1991) Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51:6304-6311.
21. Khanna KK and Jackson SP (2001) DNA double-strand breaks: signaling, repair and the cancer connection. Nat Genet 27:247-254. (Pubitemid 32201842)
22. Leahy JJ, Golding BT, Griffin RJ, Hardcastle IR, Richardson C, Rigoreau L, and Smith GC (2004) Identification of a highly potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor (NU7441) by screening of chromenone libraries. Bioorg Med Chem Lett 14:6083-6087. (Pubitemid 39531277)
23. Liu LF (1989) DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 58:351-375.
24. Long BH, Musial ST, and Brattain MG (1985) Single- and double-strand DNA breakage and repair in human lung adenocarcinoma cells exposed to etoposide and teniposide. Cancer Res 45:3106-3112. (Pubitemid 15007180)
25. Morrison C, Sonoda E, Takao N, Shinohara A, Yamamoto K, and Takeda S (2000) The controlling role of ATM in homologous recombinational repair of DNA damage. EMBO J 19:463-471. (Pubitemid 30072616)
26. O'Driscoll M, Ruiz-Perez VL, Woods CG, Jeggo PA, and Goodship JA (2003) A splicing mutation affecting expression of ataxia-telangiectasia and Rad3-related protein (ATR) results in Seckel syndrome. Nat Genet 33:497-501. (Pubitemid 36390012)
27. Okuhara K, Ohta K, Seo H, Shioda M, Yamada T, Tanaka Y, Dohmae N, Seyama Y, Shibata T, and Murofushi H (1999) A DNA unwinding factor involved in DNA replication in cell-free extracts of Xenopus eggs. Curr Biol 9:341-350. (Pubitemid 29194874)
28. Onda T, Toyoda E, Miyazaki O, Seno C, Kagaya S, Okamoto K, and Nishikawa K (2008) NK314, a novel topoisomerase II inhibitor, induces rapid DNA doublestrand breaks and exhibits superior antitumor effects against tumors resistant to other topoisomerase II inhibitors. Cancer Lett 259:99-110. (Pubitemid 350235096)
29. Osheroff N (1989) Effect of antineoplastic agents on the DNA cleavage/religation reaction of eukaryotic topoisomerase II: inhibition of DNA religation by etoposide. Biochemistry 28:6157-6160.
30. Pommier Y, Covey JM, Kerrigan D, Markovits J, and Pham R (1987) DNA unwinding and inhibition of mouse leukemia L1210 DNA topoisomerase I by intercalators. Nucleic Acids Res 15:6713-6731. (Pubitemid 17134366)
31. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, and Bonner WM (1998) DNA doublestranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 273:5858-5868. (Pubitemid 28124064)
32. Ross GM, Eady JJ, Mithal NP, Bush C, Steel GG, Jeggo PA, and McMillan TJ (1995) DNA strand break rejoining defect in xrs-6 is complemented by transfection with the human Ku80 gene. Cancer Res 55:1235-1238.
33. San Filippo J, Sung P, and Klein H (2008) Mechanism of eukaryotic homologous recombination. Annu Rev Biochem 77:229-257.
34. Schwartz DC and Cantor CR (1984) Separation of yeast chromosome-sized DNAs by pulsed field gradient gel electrophoresis. Cell 37:67-75. (Pubitemid 14079837)
35. Shiloh Y (2001) ATM and ATR: networking cellular responses to DNA damage. Curr Opin Genet Dev 11:71-77.
36. Singal PK and Iliskovic N (1998) Doxorubicin-induced cardiomyopathy. N Engl J Med 339:900-905. (Pubitemid 28446849)
37. Story MD, Mendoza EA, Meyn RE, and Tofilon PJ (1994) Pulsed-field gel electrophoretic analysis of DNA double-strand breaks in mammalian cells using photostimulable storage phosphor imaging. Int J Radiat Biol 65:523-528.
38. Tewey KM, Rowe TC, Yang L, Halligan BD, and Liu LF (1984) Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 226:466-468. (Pubitemid 14012819)
39. Toyoda E, Kagaya S, Cowell IG, Kurosawa A, Kamoshita K, Nishikawa K, Iiizumi S, Koyama H, Austin CA, and Adachi N (2008) NK314, a topoisomerase II inhibitor that specifically targets the alpha isoform. J Biol Chem 283:23711-23720.
40. Ward IM and Chen J (2001) Histone H2AX is phosphorylated in an ATR-dependent manner in response to replicational stress. J Biol Chem 276:47759-47762.
41. Zhao Y, Thomas HD, Batey MA, Cowell IG, Richardson CJ, Griffin RJ, Calvert AH, Newell DR, Smith GC, and Curtin NJ (2006) Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441. Cancer Res 66:5354-5362. (Pubitemid 43844961)
42. Ziv Y, Bar-Shira A, Pecker I, Russell P, Jorgensen TJ, Tsarfati I, and Shiloh Y (1997) Recombinant ATM protein complements the cellular A-T phenotype. Oncogene 15:159-167. (Pubitemid 27344555)